Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
Administration, Oral
Adolescent
Area Under Curve
Astrocytoma
/ drug therapy
Biological Availability
Biological Variation, Population
Brain Neoplasms
/ drug therapy
Child
Child, Preschool
Computer Simulation
Drug Administration Schedule
Drug Elimination Routes
Female
Humans
Male
Models, Biological
Mutation
Powders
/ administration & dosage
Protein Kinase Inhibitors
/ administration & dosage
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Tablets
/ administration & dosage
Vemurafenib
/ administration & dosage
Young Adult
astrocytomas
crushed tablets
pediatrics
pharmacokinetics
vemurafenib
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
26
11
2019
accepted:
12
03
2020
pubmed:
2
6
2020
medline:
1
7
2021
entrez:
2
6
2020
Statut:
ppublish
Résumé
Vemurafenib (Zelboraf) is an orally available BRAF
Substances chimiques
Powders
0
Protein Kinase Inhibitors
0
Tablets
0
Vemurafenib
207SMY3FQT
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1209-1219Subventions
Organisme : NCI NIH HHS
ID : P50 CA097257
Pays : United States
Informations de copyright
© 2020, The American College of Clinical Pharmacology.
Références
Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics. 2009;6(3):570-586.
Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346(6):420-427.
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
Agianian B, Gavathiotis E. Current insights of BRAF inhibitors in cancer: miniperspective. J Med Chem. 2018;61(14):5775-5793.
Zelboraf FDA Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf. Accessed February 21, 2019.
FDA Pharmacology Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000PharmR.pdf. Accessed November 6, 2018.
Aguilera D, Janss A, Mazewski C, et al. Successful retreatment of a child with a refractory brainstem ganglioglioma with vemurafenib. Pediatr Blood Cancer. 2016;63(3):541-543.
Bautista F, Paci A, Minard-Colin V, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61(6):1101-1103.
del Bufalo F, Carai A, Figà-Talamanca L, et al. Response of recurrent BRAFV600E mutated ganglioglioma to vemurafenib as single agent. J Transl Med. 2014;12:356.
Rush S, Foreman N, Liu A. Brainstem Ganglioglioma Successfully Treated With Vemurafenib. J Clin Oncol. 2013;31(10):e159-160.
Nicolaides TP, Li H, Solomon DA, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res. 2011;17(24):7595-7604.
Nijenhuis CM, Huitema ADR, Blank C, et al. Clinical pharmacokinetics of vemurafenib in BRAF-mutated melanoma patients. J Clin Pharmacol. 2017;57(1):125-128.
Funck-Brentano E, Alvarez JC, Longvert C, et al. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Ann Oncol. 2015.;26(7):1470-1475.
Puszkiel A, White-Koning M, Dupin N, et al. Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients. Pharmacol Res. 2016;113:709-718.
Zhang W, Heinzmann D, Grippo JF. Clinical pharmacokinetics of vemurafenib. Clin Pharmacokinet. 2017;56(9):1033-1043.
Chisholm JC, Suvada J, Dunkel IJ, et al. BRIM-P: a phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer. 2018;65(5):e26947.
FDA Clinical Pharmacology Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000ClinPharmR.pdf. Accessed November 6, 2018.
Goldwirt L, Chami I, Feugeas J-P, et al. Reply to “Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance” by Funck-Brentano et al. Ann Oncol. 2016;27(2):363-364.
Kramkimel N, Thomas-Schoemann A, Sakji L, et al. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma. Target Oncol. 2016;11(1):59-69.
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas. https://clinicaltrials.gov/ct2/show/NCT01748149. Accessed May 11, 2020.
Nicolaides T, Nazemi K, Crawford J, et al. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. In press.
Nijenhuis CM, Rosing H, Schellens JHM, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. J Pharm Biomed Anal. 2014;88:630-635.
Kieran MW, Bouffet E, Broniscer A, et al. Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed refractory low-grade glioma. J Clin Oncol. 2018;36(15_suppl):10506-10506.
Byon W, Fletcher CV, Brundage RC. Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn. 2008;35(1):101-116.
R Development Core Team. R: A language and enviroment for statistical computing. In. Vienna, Austria: R Foundation for Statistical Computing. 2010.
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1:e6.
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-Part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2(4):e38.
Ette EI, Onyiah LC. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with winsorization. Eur J Drug Metab Pharmacokinet. 2002;27(3):213-224.
Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25-36.
Liu T, Lewis T, Gauda E, Gobburu J, Ivaturi V. Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. J Clin Pharmacol. 2016;56(8):1009-1018.
Venkatasubramanian R, Fukuda T, Niu J, et al. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014;15(10):1297-1309.
Shen Y, Cai M-H, Ji W, et al. Unrepaired tetralogy of Fallot-related pathophysiologic changes reduce systemic clearance of etomidate in children. Anesth Analg. 2016;123(3):722-730.
West GB. A general model for the origin of allometric scaling laws in biology. Science. 1997;276(5309):122-126.
Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154-166.
Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143-151.
Ribas A, Zhang W, Chang I, et al. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014;54(4):368-374.
Anker van den J, Reed MD, Allegaert K, Kearns GL. Developmental changes in pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 58(suppl. 10):S10-S25.
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB. Prediction of fat-free mass in children. Clin Pharmacokinet. 2015;54(11):1169-1178.
Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother. 2000;34(9):1066-1069.
Janson B, Whittle J, Witney K, Moodie K, Callahan J, Sandhu S. Use of vemurafenib in a patient unable to swallow whole. J Oncol Pharm Pract. 2016;22(5):733-737.
Héritier S, Jehanne M, Leverger G, et al. Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis. JAMA Oncol. 2015;1(6):836-838.
Funck-Brentano E, Alvarez JC, Longvert C, et al. Reply to the letter to the editor “Plasma vemurafenib concentrations in advanced BRAFV600 mut melanoma patients: impact on tumor response and tolerance” by Funck-Brentano et al. Ann Oncol. 2016;27(2):364-365.